Inhibrx Historical Cash Flow

INBX Stock

USD 14.86 0.78 5.54%

Analysis of Inhibrx cash flow over time is an excellent tool to project Inhibrx future capital expenditures as well as to predict the amount of cash needed to cover cost of sales, R&D expenses or production expansions. Investors should almost always look for trends in cash flow indicators such as Stock Based Compensation of 26.1 M or Change In Working Capital of 16.1 M as it is a great indicator of Inhibrx ability to facilitate future growth, repay debt on time or pay out dividends.

Cash Flow Balance Sheet Income Statement

Covid

Financial Statement Analysis is much more than just reviewing and examining Inhibrx latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether Inhibrx is a good buy for the upcoming year.

Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Inhibrx. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics.

For more information on how to buy Inhibrx Stock please use our How to Invest in Inhibrx guide.

About Inhibrx Cash Flow Analysis

The Cash Flow Statement is a financial statement that shows how changes in Inhibrx balance sheet and income statement accounts affect cash and cash equivalents. It breaks the analysis down to operating, investing, and financing activities. One of the most critical aspects of the cash flow statement is liquidity, which is the degree to which Inhibrx's non-liquid assets can be easily converted into cash.

Inhibrx Cash Flow Chart

At this time, Inhibrx's Issuance Of Capital Stock is fairly stable compared to the past year. Change Receivables is likely to rise to about 749.9 K in 2024, whereas Change In Cash is likely to drop slightly above 3.9 M in 2024.

Stock Based Compensation Begin Period Cash Flow Capital Expenditures End Period Cash Flow

Stock Based Compensation

Compensation provided to employees in the form of equity or options to purchase company stock. This type of compensation is used to align the interests of employees and shareholders.

Begin Period Cash Flow

The amount of cash a company has at the beginning of a financial reporting period. It serves as the starting point for calculating the period's cash flow from operations, investing, and financing activities.

Capital Expenditures

Capital Expenditures are funds used by Inhibrx to acquire physical assets such as property, industrial buildings or equipment. This type of outlay is used by management to increase the scope of Inhibrx operations. These expenditures can include everything from repairing an office equipment, building a brand new facility, or writing new software.

Most accounts from Inhibrx's cash flow statement are interrelated and interconnected. However, analyzing cash flow statement accounts one by one will only give a small insight into Inhibrx current financial condition. On the other hand, looking into the entire matrix of cash flow statement accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Inhibrx. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of labor statistics.

For more information on how to buy Inhibrx Stock please use our How to Invest in Inhibrx guide.At this time, Inhibrx's Issuance Of Capital Stock is fairly stable compared to the past year. Change Receivables is likely to rise to about 749.9 K in 2024, whereas Change In Cash is likely to drop slightly above 3.9 M in 2024.

	2021	2022	2023	2024 (projected)
Sale Purchase Of Stock	43.8M	129.7M	116.8M	82.8M
Issuance Of Capital Stock	40.2M	127.4M	200M	210M

Sale Purchase Of Stock Issuance Of Capital Stock

Inhibrx cash flow statement Correlations

	Change In Cash	Net Borrowings	Stock Based Compensation	Free Cash Flow	Change In Working Capital	Begin Period Cash Flow	Depreciation	Other Non Cash Items	Capital Expenditures	Change To Operating Activities	Net Income	End Period Cash Flow	Change To Netincome	Change To Liabilities	Change To Inventory	Investments	Change To Account Receivables	Issuance Of Capital Stock	Sale Purchase Of Stock	Change Receivables	Cash And Cash Equivalents Changes	Cash Flows Other Operating
Change In Cash		0.35	0.2	-0.17	0.28	0.04	0.41	0.48	-0.11	0.49	-0.23	0.44	0.27	0.35	-0.02	0.27	0.47	0.38	0.14	0.28	0.23	0.38
Net Borrowings	0.35		0.95	-0.96	0.65	0.92	0.69	0.54	0.77	0.55	-0.96	0.97	0.91	0.68	-0.75	-0.71	-0.21	0.92	-0.42	0.97	0.19	0.69
Stock Based Compensation	0.2	0.95		-0.98	0.56	0.97	0.77	0.56	0.82	0.34	-0.98	0.96	0.98	0.67	-0.85	-0.69	-0.33	0.88	-0.65	0.92	-0.05	0.48
Free Cash Flow	-0.17	-0.96	-0.98		-0.64	-0.98	-0.71	-0.54	-0.87	-0.45	0.99	-0.95	-0.94	-0.69	0.78	0.79	0.38	-0.92	0.55	-0.94	-0.08	-0.57
Change In Working Capital	0.28	0.65	0.56	-0.64		0.55	0.51	0.69	0.81	0.82	-0.72	0.6	0.55	0.89	-0.15	-0.72	-0.18	0.79	0.1	0.65	0.54	0.73
Begin Period Cash Flow	0.04	0.92	0.97	-0.98	0.55		0.63	0.42	0.85	0.35	-0.96	0.91	0.91	0.58	-0.82	-0.8	-0.48	0.87	-0.63	0.92	-0.01	0.49
Depreciation	0.41	0.69	0.77	-0.71	0.51	0.63		0.89	0.62	0.14	-0.76	0.73	0.88	0.78	-0.66	-0.35	0.14	0.65	-0.53	0.59	-0.15	0.22
Other Non Cash Items	0.48	0.54	0.56	-0.54	0.69	0.42	0.89		0.6	0.34	-0.63	0.57	0.67	0.82	-0.29	-0.34	0.31	0.62	-0.24	0.42	0.04	0.25
Capital Expenditures	-0.11	0.77	0.82	-0.87	0.81	0.85	0.62	0.6		0.46	-0.89	0.72	0.78	0.77	-0.54	-0.93	-0.42	0.82	-0.39	0.77	0.15	0.5
Change To Operating Activities	0.49	0.55	0.34	-0.45	0.82	0.35	0.14	0.34	0.46		-0.5	0.52	0.27	0.58	0.08	-0.5	-0.15	0.7	0.39	0.58	0.75	0.86
Net Income	-0.23	-0.96	-0.98	0.99	-0.72	-0.96	-0.76	-0.63	-0.89	-0.5		-0.95	-0.95	-0.76	0.75	0.78	0.32	-0.94	0.5	-0.94	-0.13	-0.6
End Period Cash Flow	0.44	0.97	0.96	-0.95	0.6	0.91	0.73	0.57	0.72	0.52	-0.95		0.93	0.67	-0.74	-0.61	-0.24	0.94	-0.51	0.94	0.08	0.6
Change To Netincome	0.27	0.91	0.98	-0.94	0.55	0.91	0.88	0.67	0.78	0.27	-0.95	0.93		0.74	-0.86	-0.6	-0.21	0.83	-0.65	0.87	-0.09	0.43
Change To Liabilities	0.35	0.68	0.67	-0.69	0.89	0.58	0.78	0.82	0.77	0.58	-0.76	0.67	0.74		-0.42	-0.56	-0.05	0.73	-0.09	0.68	0.34	0.63
Change To Inventory	-0.02	-0.75	-0.85	0.78	-0.15	-0.82	-0.66	-0.29	-0.54	0.08	0.75	-0.74	-0.86	-0.42		0.42	0.24	-0.52	0.7	-0.76	0.22	-0.28
Investments	0.27	-0.71	-0.69	0.79	-0.72	-0.8	-0.35	-0.34	-0.93	-0.5	0.78	-0.61	-0.6	-0.56	0.42		0.52	-0.75	0.25	-0.72	-0.29	-0.54
Change To Account Receivables	0.47	-0.21	-0.33	0.38	-0.18	-0.48	0.14	0.31	-0.42	-0.15	0.32	-0.24	-0.21	-0.05	0.24	0.52		-0.32	0.28	-0.34	0.0	-0.15
Issuance Of Capital Stock	0.38	0.92	0.88	-0.92	0.79	0.87	0.65	0.62	0.82	0.7	-0.94	0.94	0.83	0.73	-0.52	-0.75	-0.32		-0.36	0.89	0.22	0.65
Sale Purchase Of Stock	0.14	-0.42	-0.65	0.55	0.1	-0.63	-0.53	-0.24	-0.39	0.39	0.5	-0.51	-0.65	-0.09	0.7	0.25	0.28	-0.36		-0.34	0.78	0.32
Change Receivables	0.28	0.97	0.92	-0.94	0.65	0.92	0.59	0.42	0.77	0.58	-0.94	0.94	0.87	0.68	-0.76	-0.72	-0.34	0.89	-0.34		0.29	0.77
Cash And Cash Equivalents Changes	0.23	0.19	-0.05	-0.08	0.54	-0.01	-0.15	0.04	0.15	0.75	-0.13	0.08	-0.09	0.34	0.22	-0.29	0.0	0.22	0.78	0.29		0.79
Cash Flows Other Operating	0.38	0.69	0.48	-0.57	0.73	0.49	0.22	0.25	0.5	0.86	-0.6	0.6	0.43	0.63	-0.28	-0.54	-0.15	0.65	0.32	0.77	0.79

Click cells to compare fundamentals

Inhibrx Account Relationship Matchups

Inhibrx cash flow statement Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Change In Cash	9.4M	117.1M	2.6M	142.6M	4.1M	3.9M
Net Borrowings	33.8M	41.4M	40.0M	128.9M	148.2M	155.6M
Stock Based Compensation	4.0M	5.0M	15.0M	17.8M	24.8M	26.1M
Free Cash Flow	(33.9M)	(49.3M)	(81.2M)	(116.0M)	(197.9M)	(188.0M)
Change In Working Capital	3.5M	12.7M	(17.5M)	3.2M	15.3M	16.1M
Begin Period Cash Flow	2.1M	11.5M	128.7M	131.3M	273.9M	287.6M
Total Cashflows From Investing Activities	(1.8M)	(1.4M)	(809K)	(686K)	(617.4K)	(648.3K)
Other Cashflows From Financing Activities	37.5M	166.5M	83.8M	128.8M	202.0M	212.1M
Depreciation	1.2M	1.0M	1.2M	1.2M	1.2M	979.1K
Other Non Cash Items	9.6M	11.6M	2.7M	5.1M	6.7M	4.6M
Capital Expenditures	1.8M	1.4M	864K	686K	4.6M	4.8M
Total Cash From Operating Activities	(32.1M)	(48.0M)	(80.3M)	(115.3M)	(193.3M)	(183.6M)
Change To Operating Activities	(2.5M)	7.8M	(11.0M)	5.7M	6.6M	6.9M
Net Income	(51.4M)	(76.1M)	(81.8M)	(145.2M)	(241.4M)	(229.3M)
Total Cash From Financing Activities	43.3M	166.5M	83.8M	258.6M	202.0M	111.3M
End Period Cash Flow	11.5M	128.7M	131.3M	273.9M	277.9M	291.8M
Change To Netincome	6.4M	4.3M	16.5M	20.5M	23.5M	24.7M
Change To Liabilities	5.5M	4.8M	(6.3M)	6.9M	7.9M	8.3M
Change To Inventory	(672K)	(2.5M)	7.8M	(11.0M)	(9.9M)	(9.4M)
Investments	(1.8M)	(1.4M)	(809K)	(686K)	(4.6M)	(4.4M)
Change To Account Receivables	491K	117K	(167K)	130K	(521K)	(495.0K)
Issuance Of Capital Stock	12M	136.9M	40.2M	127.4M	200M	210M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

RSI	Rush Street Interactive
OKTA	Okta Inc
BAC	Bank of America

Additional Tools for Inhibrx Stock Analysis

When running Inhibrx's price analysis, check to measure Inhibrx's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Inhibrx is operating at the current time. Most of Inhibrx's value examination focuses on studying past and present price action to predict the probability of Inhibrx's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Inhibrx's price. Additionally, you may evaluate how the addition of Inhibrx to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Inhibrx Historical Cash Flow

About Inhibrx Cash Flow Analysis

Inhibrx Cash Flow Chart

Stock Based Compensation

Begin Period Cash Flow

Capital Expenditures

Inhibrx cash flow statement Correlations

Inhibrx Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Inhibrx cash flow statement Accounts

Also Currently Popular

Additional Tools for Inhibrx Stock Analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Net Income	+ 0.99	Free Cash Flow
Change To Netincome	+ 0.98	Stock Based Compensation
End Period Cash Flow	+ 0.97	Net Borrowings
Change Receivables	+ 0.97	Net Borrowings
Begin Period Cash Flow	+ 0.97	Stock Based Compensation
End Period Cash Flow	+ 0.96	Stock Based Compensation

Begin Period Cash Flow	- 0.98	Free Cash Flow
Net Income	- 0.98	Stock Based Compensation
Free Cash Flow	- 0.98	Stock Based Compensation
Net Income	- 0.96	Begin Period Cash Flow
Net Income	- 0.96	Net Borrowings
Free Cash Flow	- 0.96	Net Borrowings